Drug Search Results
More Filters [+]

Trebananib

Alternative Names: trebananib, AMG386, AMG-386, AMG 386
Latest Update: 2024-10-22
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Angiogenesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trebananib

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Colorectal Cancer|Kidney Diseases|Melanoma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Small Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT03239145

P1

Active, not recruiting

Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Colorectal Cancer|Ovarian Cancer|Melanoma|Kidney Diseases

2025-02-28

Recent News Events